titres
[용어속성] Term
A serological survey of severe acute respiratory syndrome coronavirus 2 in dogs in Wuhan
우한에서 개를 대상으로 한 중증급성호흡기증후군 코로나바이러스 2의 혈청학적 조사
Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
canine
cats
caused
CCV
collected
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
cross-reactivity
decrease
dog
effective
ELISA
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
exhibited
Health crisis
higher risk
infected with SARS-CoV-2
Infection
infection rate
infection rates
Neutralizing
Neutralizing antibodies
neutralizing antibody
Novel coronavirus
novel coronavirus disease
outbreak
pandemic
positive
Prevalence
prevention of COVID-19
public health crisis
ranged
RBD
Receptor-binding domain
reported
respiratory
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-specific neutralizing antibody
sera
serological
serological investigation.
serological survey
seropositive
serum sample
severe acute respiratory syndrome Coronavirus
specific neutralizing antibodies
Stage
the receptor-binding domain
the SARS-CoV-2
titre
titres
Transmission
Wuhan
[DOI] 10.1111/tbed.14024 PMC 바로가기 [Article Type] Article
[DOI] 10.1111/tbed.14024 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
중국 성인을 대상으로 한 SARS-CoV-2 ARCoV mRNA 백신의 안전성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1상 시험
Clinical Trial
[키워드] abnormal change
abnormal changes
Academy
administration
adverse event
adverse events
Adverse reaction
Adverse reactions
All participant
All participants
analyses
Analysis
Anti-RBD IgG
anti-SARS-CoV-2
Antibody titre
assigned
baseline
block
Block randomisation
caused
cellular immune responses
China
Chinese
clinical testing
conducted
convalescent patient
Convalescent patients
COVID-19 pandemic
development
domain
dose
dose-escalation
doses
double-blind
effective vaccine
Effective vaccines
eligible participant
ELISA
ELISPOT
ENCODE
enrolled
enzyme
enzyme-linked immunospot
expected
exploratory
Fever
first vaccination
FIVE
foundation
grade 3
group
groups
highest
hospital
humoral
humoral immune responses
Humoral response
humoral responses
IFN-γ
IL-2
immune
immune response
immune responses
immunogenicity
incidence
individual
Intramuscular injection
investigators
Laboratory
laboratory analyses
Laboratory test
Laboratory tests
live SARS-CoV-2
lowest
majority
Medical Science
Medical Sciences
Mild
moderate
mRNA vaccine
natural
neutralisation assays
Neutralising Antibodies
neutralising antibody
observation
outcome
participant
Participants
peaked
Phase 1
phase 1 trial
Placebo
placebo group
placebo-controlled
Primary outcome
pseudovirus
randomised
Randomly
RBD
RBD IgG
RBD-specific IgG
receive
Registered
reported
research and development
resolved
Safe
Safety
safety analyses
safety profile
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-specific T-cell response
SARS-CoV-2-specific T-cell responses
Science
screened
second dose
second vaccination
secondary outcome
Serious Adverse Event
Serious Adverse Events
Seven
significantly
Specific
Specific T-cell response
Spike protein
Support
systemic adverse event
T-cell Response
T-cell responses
the placebo group
the SARS-CoV-2
titre
titres
Tolerability
treatment allocation
Trial
vaccination
Vaccine
vaccine dose
vaccine doses
were assessed
were given
with COVID-19
Zhejiang
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial
Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques
히말라야 원숭이에서 SARS-CoV-2 감염 후 면역 및 질병 매개변수에 대한 에어로졸 전달 BCG 백신의 영향
Immunology
[키워드] Activation
acute respiratory syndrome
adaptive
aerosol
Aerosol BCG vaccination
antibody
Antibody-mediated immunity
antiviral immune response
applied
bacille Calmette-Guérin
BAL
BCG
BCG vaccination
Bronchoalveolar lavage
cell-mediated immune response
cellular
challenge
chemokine
Classical CD14+ monocyte
Classical CD14+ monocytes
clearance
collected
comparable
Concentration
contribute
coronavirus disease
Coronavirus disease 2019
Coronavirus-2
COVID-19
COVID-19 disease severity
cross-protection
cross-protective
cross-reactive
cytokine
disease
disease pathology
disease severity
early disease
ENhance
exceeded
groups
Heterologous
High dose
Histopathology
Humoral immunity
hypothesised
immune cells
immune mechanism
immune response
immune responses
immune signature
Immunity
immunological parameters
indicated
induce
Infection
influence
initial
innate immune
innate immune cell
Innate immune cells
Innate immunity
Intervention
intrabronchial
intranasal
macaque
macaques
marker
mechanism
Monocytes
nasal
nasal and pharyngeal swabs
natural infection
non-specific
Occurrence
parameter
pharyngeal
populations
primary site
priming
quantified
reduce
respiratory
respiratory pathogen
rhesus macaque
rhesus macaques
SARS-CoV-2
secretion
severe acute respiratory syndrome Coronavirus
subsequent
susceptible
swabs
T-cell
T-cells
the disease
tissue
tissue sample
titre
titres
trained immunity
Tuberculosis
tuberculosis vaccine
Vaccine
Viral
Viral RNA
virus
[DOI] 10.3389/fimmu.2021.801799 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.801799 PMC 바로가기 [Article Type] Immunology
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Research
[키워드] Analysis
Anti-RBD IgG
antibody
assays
asymptomatic infection
asymptomatic infections
Beta
circulating variant
collected
convalescent
coronavirus disease
COVID-19
declined
decrease
Delta
detectable
disease
illness onset
Immunity
Infection
laboratory confirmation
longitudinal
majority
microneutralization
Mild
NAb
Neutralization assay
Neutralizing activity
neutralizing antibody
neutralizing response
pandemic
peaked
persistent
plasma sample
pseudotyped
reduced
response
Result
reveal
SARS-CoV-2
significantly
symptomatic
tested
These data
titre
titres
undetectable
vaccination
Vaccination strategies
variants
[DOI] 10.1038/s41564-021-01051-2 [Article Type] Research
[DOI] 10.1038/s41564-021-01051-2 [Article Type] Research
Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status
Observational Study
[키워드] Abstract
anti-SARS-CoV-2 vaccination
antibody
association
baseline
Biomarker
Biomarkers
blood sample
BNT162b2
cohort study
collected
Concentration
concentrations
correlated
COVID-19 mRNA Vaccination
disease severity
first dose
Glutathione peroxidase
had no
Health
Health care worker
healthy
highest
humoral immune response
Image
immune response
immune system
mortality risk
neutralising
Neutralising activity
neutralising antibody
pandemic
participant
patients with COVID-19
peroxidase
quantified
reported
SARS-CoV-2
SARS-CoV-2 IgG
SARS-CoV-2 vaccination
SARS-CoV-2 vaccines
Se deficiency
second dose
Selenium
Selenoprotein P
serum
significantly
titre
titres
vaccination
Vaccine
[DOI] 10.1016/j.redox.2022.102242 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1016/j.redox.2022.102242 PMC 바로가기 [Article Type] Observational Study
Humoral immune response after different SARS-CoV-2 vaccination regimens
상이한 SARS-COV-2 백신 접종 요법 후 체액 면역 반응
Research Article
[키워드] age
Alpha
anti-SARS-CoV-2
anti-SARS-CoV-2 IgG
antibody
Antibody Response
Antigen
AstraZeneca
avidity
AZD1222
B.1.1.7
B.1.1.7 variant
B.1.617.2
binding
BNT162b2
boost
booster vaccination
ChAdOx1
ChAdOx1 nCoV-19
comparable
Concentration
correlation
COVID-19
cVNT
delta variant
examined
first vaccination
followed by
Heterologous
homologous
humoral immune response
Humoral immunity
IgG
IgG antibodies
IgG antibody
immune response
immunoblot
Immunoglobulin
Immunoglobulin G
individual
investigation
leads
Maturity process
Moderna
mRNA
mRNA vaccine
neutralisation test
Neutralising Antibodies
Occurrence
Pfizer/BioNTech
Prevalence
RBD
Receptor binding domain
recipient
reduction in
regimen
Result
robust
S-protein
SARS-CoV-2
SARS-CoV-2 antigen
SARS-CoV-2 antigens
SARS-CoV-2 nucleoprotein
SARS-CoV-2 spike
SARS-CoV-2 vaccination
sera
Seroconversion
significantly higher
significantly lower
strength
subunit
supplementary material
sVNT
tested
the antibody response
the RBD
the SARS-CoV-2
the vaccine
titre
titres
trimeric
vaccination
Vaccination schemes
Vaccine
vaccine dose
vaccinee
variant
Virus neutralisation
Virus variants of concern
VoC
was done
was measured
was used
were measured
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
B 세포 만성 림프구성 백혈병 백신 접종 환자에서 SARS-CoV-2 델타 변이체 중화 장애
Research
[키워드] Adenovirus
adenovirus-based
antibody
Antibody Response
Antibody responses
B cell
BTKi therapy
CD20
Chronic lymphocytic leukaemia
CLL
CLL patient
CLL patients
control group
controls
COVID
COVID-19 vaccination
delta variant
dominant
dual
failure
functional
Gender
groups
healthy controls
healthy donor
healthy donors
immune protection
Immune suppression
Immunotherapy
Impaired
impaired antibody response
impaired antibody responses
indicate
Leukaemia
magnitude
mRNA
neutralisation
Patient
patient cohort
post treatment
Post-vaccine
Predictive
prophylactic antibiotics
reduced
respond
responders
responses
Result
risk
SARS-CoV-2
SARS-CoV-2 delta
SARS-COV-2 infection
sera
Seroconversion
serum
spike-specific antibody response
stability
supplementary material
the SARS-CoV-2
titre
titres
Treatment
vaccination
Vaccine
vaccine platform
variant
[DOI] 10.1186/s13045-021-01219-7 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13045-021-01219-7 PMC 바로가기 [Article Type] Research
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
성인에서 홍역 벡터 기반 SARS-CoV-2 백신 후보 V591의 안전성 및 면역원성: 1/2상 무작위, 이중 맹검, 위약 대조, 용량 범위 시험 결과
Clinical Trial
[키워드] Adverse
adverse events
anti-SARS-CoV-2
assigned
convalescent serum
COVID-19
COVID-19 disease
Culture
Day
death
dose
double-blind
event
fatigue
headache
healthy
humoral immunogenicity
immunogenicity
Inc.
infectious dose
injection
Injection-site pain
Intramuscular injection
median
multicentre
myalgia
neutralising antibody
occurred
Older
participant
Placebo
placebo-controlled
randomised
response
Safety
SARS-CoV-2
SARS-CoV-2 vaccine
screened
secondary
secondary outcome
Serious Adverse Event
Serious Adverse Events
serum
Sharp
single dose
subsidiary
TCID
tissue
tissue culture
titre
titres
Trial
USA
Vaccine
[DOI] 10.1016/j.ebiom.2021.103811 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.ebiom.2021.103811 PMC 바로가기 [Article Type] Clinical Trial
Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles
Article
[키워드] Affect
association
autoantibody
Autoimmunity
Biomarker
Biomarkers
Blood
blood cell count
cell profile
cell profiles
Clinical outcome
clinical outcomes
Concentration
Course
Cytokines
demonstrated
GM-CSF
HSCT
HSCT patients
HSCT recipient
Hypothesis
IFNα
IFNγ
IL-10
IL-1α
IL-6
immune
Immunological disorders
immunomodulatory
individual
infections
Inflammatory
investigated
leukocyte
Patient
plasma
Platelet
significant difference
Stem cell transplantation
tested
titres
trajectory
Transplant immunology
variable
were measured
[DOI] 10.1038/s41598-021-01952-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-021-01952-6 PMC 바로가기 [Article Type] Article